Meta analysis on protection effect of Rotarix oral rotavirus vaccine

  Objective   To evaluate the effect of Rotarix vaccine to prevent rotavirus gastroenteritis worldwide, and provide a better scientific basis for Rotarix vaccine use in regions with high and low rotavirus infection mortality.

  Methods   A total of 63 990 subjects were included in this analysis, including 27 725 subjects in low-mortality region and 36 265 subjects in high-mortality region. Software Revman 5.3 was used for statistical analysis.

  Results   In low-mortality region, the protective rates of Rotarix vaccine against rotavirus gastroenteritis (VE_RVGE) and severe rotavirus gastroenteritis (VE_SRVGE) were 73% (95% CI: 58%–82%) and 89% (95% CI: 80%–94%), respectively, the protective rates against rotavirus gastroenteritis (VERVGE) and severe rotavirus gastroenteritis in yellow race (VE_SRVGE) were 69% (95% CI: 39%–84%) and 91% (95% CI: 74%–97%) and VERVGE and severe rotavirus gastroenteritis in white race (VE_SRVGE) were 78% (95% CI: 73%–83%) and 90% (95% CI: 85%–93%). In high-mortality region, Rotarix vaccine's VERVGE and severe rotavirus gastroenteritis (VE_SRVGE) were 53% (95% CI: 27%–70%) and 70% (95% CI: 42%–85%), respectively, the VERVGE and severe rotavirus gastroenteritis (VE_SRVGE) in yellow race were 61% (95% CI: 45%–73%) and 80% (95% CI: 68%–87%) and the VERVGE and severe rotavirus gastroenteritis (VE_SRVGE) in black race were 43% (95% CI: −98%–68%) and 42% (95% CI: 25%–56%) respectively.

  Conclusion   Rotarix vaccine is safe and effective to prevent rotavirus gastroenteritis of any severity in any region, and has better protective effect against severe rotavirus gastroenteritis. Rotarix vaccine has better protective effect against rotavirus gastroenteritis of any severity in white race than in yellow race in low-mortality region. Rotarix vaccine is more effective in protecting from rotavirus gastroenteritis of any severity in yellow race than in black race in high-mortality region.